{"product_id":"celltrion-swot-analysis","title":"Celltrion SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCelltrion’s cutting-edge biosimilar portfolio and global manufacturing scale position it as a biosolutions leader, yet regulatory complexities and competitive pressures pose clear risks; our full SWOT unpacks these dynamics with financial context and strategic options. Purchase the complete SWOT analysis to receive a professionally formatted Word report plus an editable Excel matrix for investor-ready planning and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Vertical Production Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelltrion’s fully integrated model—from cell line R\u0026amp;D to global distribution—cuts COGS and boosts margins; in 2024 biosimilars made ~70% of revenue (KRW 3.1 trillion of KRW 4.4 trillion), reflecting scale-driven pricing power.\u003c\/p\u003e\n\u003cp\u003eVertical control shortens scale-up time: plants in Incheon and Songdo hit combined capacity ~120,000L in 2024, enabling rapid supply to EU\/US markets and reducing third-party risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Global Biosimilar Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Celltrion is a global biosimilar leader, with Remsima holding about 60% share in Europe and roughly 30% in the U.S., and Truxima capturing strong oncology uptake; these products drove biosimilar revenues of ~KRW 1.2 trillion in 2024, giving Celltrion a stable cash base and high trust among hospitals and major pharmacy benefit managers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Direct Sales Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelltrion has moved to direct sales in Europe and North America, removing third-party distributors and raising gross margins by ~4–6 percentage points versus prior fiscal years; this captured roughly $180–220M in FY2024–2025 incremental margin. The shift enabled agile, country-level marketing and pricing, accelerating uptake of Zymfentra and Yuflyma to 14% and 11% market share in targeted segments by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecord-Breaking Financial Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelltrion posted record 2025 results: revenue exceeded 4.0 trillion won and operating profit topped 1.0 trillion won for the first time, driven by a high-margin mix where new products made up over 50% of sales.\u003c\/p\u003e\n\u003cp\u003eMerger-related costs from the 2023 integration with Celltrion Healthcare have been resolved, normalizing the balance sheet and supporting cash flow and leverage improvement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 revenue \u0026gt;4.0 trillion won\u003c\/li\u003e\n\u003cli\u003e2025 operating profit \u0026gt;1.0 trillion won\u003c\/li\u003e\n\u003cli\u003eNew products \u0026gt;50% of sales\u003c\/li\u003e\n\u003cli\u003eMerger costs from 2023 resolved\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePioneering Subcutaneous Formulation Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelltrion’s Zymfentra, approved by the FDA in 2023 as the first subcutaneous infliximab, proves technical leadership and lets the company price above IV biosimilars; U.S. launch volumes hit ~$180m in 2024, validating payer acceptance and patient uptake.\u003c\/p\u003e\n\u003cp\u003eThe SC format boosts convenience, cuts clinic time, and creates a quasi-new-drug positioning that deters biosimilar erosion and supports higher margins vs IV infliximab.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst FDA SC infliximab (2023)\u003c\/li\u003e\n\u003cli\u003eU.S. sales ≈ $180m in 2024\u003c\/li\u003e\n\u003cli\u003ePremium pricing vs IV biosimilars\u003c\/li\u003e\n\u003cli\u003eDifferentiator vs standard biosimilars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelltrion cuts COGS with 120kL scale—biosimilars drive KRW4.4T revenue, \u0026gt;KRW1T op profit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelltrion’s integrated model and large-scale plants (≈120,000L capacity) cut COGS, driving biosimilars to ~70% of 2024 revenue (KRW 3.1T of KRW 4.4T) and 2025 revenue \u0026gt;KRW 4.0T with operating profit \u0026gt;KRW 1.0T; Remsima ~60% EU, Truxima strong oncology share, Zymfentra SC US sales ≈$180M (2024) plus direct-sales margin lift (~+4–6pp).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eKRW 4.4T\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;KRW 4.0T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars share\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant capacity\u003c\/td\u003e\n\u003ctd\u003e≈120,000L\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating profit\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;KRW 1.0T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZymfentra US sales\u003c\/td\u003e\n\u003ctd\u003e$180M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Celltrion’s internal and external business factors, outlining strengths in biologics manufacturing and global partnerships, weaknesses in pricing pressures and patent reliance, opportunities from biosimilar expansion and pipeline diversification, and threats from regulatory shifts and competitive biosimilars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a clear SWOT snapshot of Celltrion for rapid strategic alignment and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Initial R\u0026amp;D and Clinical Trial Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelltrion’s shift to novel drugs like ADCs and multispecifics demands massive upfront R\u0026amp;D; maintaining a 16‑product new drug pipeline plus 11 commercial biosimilars pushed R\u0026amp;D spend to about KRW 390 billion (≈ USD 300M) in 2024, pressuring short‑term liquidity and lowering 2024 free cash flow margin to roughly 2.1%. Clinical delays or failures would worsen leverage—net debt\/EBITDA rose to ~1.6x in FY2024—so finance ratios and cash flow face notable strain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Autoimmune and Oncology Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite global sales, Celltrion generated ~65% of 2024 revenue from autoimmune and oncology biosimilars (KRW 2.1 trillion of KRW 3.2 trillion total), leaving limited therapeutic diversification; this concentration raises exposure to regulatory shifts, patent outcomes, or new non-biologic entrants like oral small molecules and cell therapies. A major pricing war or a disruptive therapy in these fields could cut top-line and margin quickly, stressing cash flow and R\u0026amp;D funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity Post-Merger\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePost-merger integration after Celltrion’s 2023 tie-up with Celltrion Healthcare has created operational complexity: combining a global direct sales force of ~7,000 staff and five major manufacturing sites has required new ERP and quality systems, causing temporary admin inefficiencies.\u003c\/p\u003e\n\u003cp\u003eDuring 2024 the company reported inventory days rising from 85 to 102 and cost-of-sales margin pressure—COGS to sales up ~220 basis points—reflecting harmonization challenges across supply chains and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Experience in Novel Drug Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile Celltrion dominates biosimilars—2024 revenue KRW 2.1 trillion from biologics—its track record commercializing first-in-class small-molecule or novel biologics lags behind Big Pharma with global launch experience.\u003c\/p\u003e\n\u003cp\u003eMoving to a dual-track model needs deeper specialist engagement and payer navigation; mistakes could cut initial uptake, as seen when mid-sized firms average 18–30 months to reach peak launch volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 biologics revenue: KRW 2.1 trillion\u003c\/li\u003e\n\u003cli\u003eLimited novel-drug launch pedigree vs global peers\u003c\/li\u003e\n\u003cli\u003eRequires stronger KOL (key opinion leader) ties and payer evidence\u003c\/li\u003e\n\u003cli\u003eTypical 18–30 month learning curve to peak uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to South Korean Economic and Regulatory Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a South Korea-based biopharma giant, Celltrion is exposed to domestic economic swings; Korea GDP fell 0.3% q\/q in Q4 2024, which can compress healthcare spending and demand for biologics.\u003c\/p\u003e\n\u003cp\u003eRegulatory moves on drug pricing or R\u0026amp;D tax credits—Korea cut some pharma reimbursements in 2023—could reduce margins and capex for new projects.\u003c\/p\u003e\n\u003cp\u003eListed on KOSPI, Celltrion’s share price tracks regional risk: KOSPI fell 12% in 2024 amid geopolitics, amplifying volatility and financing costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDP Q4 2024 −0.3% q\/q\u003c\/li\u003e\n\u003cli\u003eKOSPI 2024 decline ≈12%\u003c\/li\u003e\n\u003cli\u003ePolicy shifts hit margins, R\u0026amp;D budgets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelltrion: Heavy R\u0026amp;D, biologics concentration and stretched liquidity raise execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelltrion’s heavy R\u0026amp;D (KRW 390B ≈ USD 300M in 2024) and 16‑drug novel pipeline strain liquidity—FCF margin ~2.1% and net debt\/EBITDA ~1.6x (FY2024). Revenue remains concentrated: biologics KRW 2.1T of KRW 3.2T (≈65%), raising regulatory and competitive risk. Post‑merger ops and inventory days (85→102) increased costs; limited novel‑drug launch pedigree slows peak uptake (18–30 months).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eKRW 390B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF margin\u003c\/td\u003e\n\u003ctd\u003e2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e1.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics revenue\u003c\/td\u003e\n\u003ctd\u003eKRW 2.1T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e102\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCelltrion SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is not a sample but the real, editable analysis you'll download post-purchase. Buy now to unlock the complete, structured, and ready-to-use Celltrion SWOT report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752377332089,"sku":"celltrion-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/celltrion-swot-analysis.png?v=1772240228","url":"https:\/\/matrixbcg.com\/products\/celltrion-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}